Piperacillin/Tazobactam vs Meropenem for Infections
(VPS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.
Who Is on the Research Team?
Daniel Freilich, MD
Principal Investigator
Bassett Medical Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either vancomycin plus piperacillin/tazobactam or vancomycin plus meropenem to assess renal effects
Follow-up
Participants are monitored for safety and effectiveness after treatment, including kidney injury biomarkers and infectious complications
What Are the Treatments Tested in This Trial?
Interventions
- Meropenem
- Piperacillin/Tazobactam
How Is the Trial Designed?
2
Treatment groups
Active Control
Vancomycin plus piperacillin/tazobactam
Vancomycin plus meropenem
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bassett Healthcare
Lead Sponsor
Johns Hopkins University
Collaborator
Patient-Centered Outcomes Research Institute
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.